Yanjun Li

TL;DR: It is shown that YY1 alters tumor cell metabolism by activating glucose-6-phosphate dehydrogenase (G6PD), the rate-limiting enzyme in the pentose phosphate pathway, which links its function in tumorigenesis to metabolic reprogramming in tumor cells.

TL;DR: This study showed that YY1 suppresses fatty acid β-oxidation, leading to increase of cellular triglyceride level and lipid accumulation in HCC cells, and subsequently induction of the tumorigenesis potential of H CC cells, providing evidences regarding the potential of YY 1 as a target for lipid metabolism-based anti-tumor therapy.

TL;DR: This work revealed that YY1 activates GLUT3 transcription by directly binding to its promoter and, concomitantly, enhances tumor cell aerobic glycolysis and showed that clinical drug oxaliplatin suppresses colon carcinoma cell proliferation by inhibiting the YY 1/GLUT3 axis.

TL;DR: Findings reveal NeuroD1 as a novel regulator of the p53/p21 axis, underscoring its importance in promoting non–neural malignancies and insight into the transcriptional regulation of p53 is provided.

TL;DR: In this paper, the authors showed that NeuroD1 is positively correlated with glucose-6-phosphate dehydrogenase (G6PD), the rate-limiting enzyme in the pentose phosphate pathway (PPP), in colorectal cancer cells.